Faeth Therapeutics Inc (SNSE): Next-Year EPS Estimate 91.78%
As of 2026-06-15, Faeth Therapeutics Inc (SNSE) has a next-year EPS growth estimate of 91.78%.
On 2026-06-11, analyst consensus for SNSE's next-year EPS growth shifted from 92.04% to 91.78% — a negative change of 0.26 percentage points. The revised estimate has been sustained across 3 subsequent trading sessions. Current-year growth is projected at -508.07%.
Current Snapshot
- Sector
- Healthcare
- Industry
- Biotechnology
- EPS growth next year
- 91.78%
- EPS growth this year
- -508.07%
- EPS next quarter (est)
- -$5.04
- Last price
- $13.85
EPS Revision History
| Date | EPS Next Y | EPS This Y | Next Q (est) | Price |
|---|---|---|---|---|
| 2026-06-15 | 91.78% | -508.07% | -$5.04 | $13.85 |
| 2026-06-14 | 91.78% | -508.07% | -$5.04 | $13.00 |
| 2026-06-11 | 91.78% | -508.07% | -$5.04 | $10.79 |
| 2026-06-10 | 92.04% | -389.77% | -$3.37 | $11.41 |
| 2026-06-09 | 92.04% | -389.77% | -$3.37 | $12.63 |
| 2026-06-08 | 92.04% | -389.77% | -$3.37 | $13.00 |
| 2026-06-07 | 92.04% | -389.77% | -$3.37 | $14.65 |
| 2026-06-04 | 92.04% | -389.77% | -$3.37 | $16.60 |
| 2026-06-03 | 92.17% | -389.25% | -$3.34 | $15.85 |
| 2026-06-02 | 92.17% | -389.25% | -$3.34 | $16.09 |
| 2026-06-01 | 92.17% | -389.25% | -$3.34 | $19.79 |
| 2026-05-31 | 92.17% | -389.25% | -$3.34 | $21.14 |
| 2026-05-28 | 90.52% | -508.13% | -$8.20 | $17.59 |
| 2026-05-27 | 90.52% | -508.13% | -$8.20 | $16.65 |
| 2026-05-26 | 90.52% | -508.13% | -$8.20 | $16.47 |
| 2026-05-25 | 90.52% | -508.13% | -$8.20 | $17.79 |
| 2026-05-24 | 90.52% | -508.13% | -$8.20 | $17.79 |
| 2026-05-21 | 90.52% | -508.13% | -$8.20 | $17.56 |
| 2026-05-20 | 90.52% | -508.13% | -$8.20 | $17.58 |
| 2026-05-19 | 90.52% | -508.13% | -$8.20 | $16.77 |
| 2026-05-18 | 90.52% | -508.13% | -$8.20 | $19.91 |
Screen Performance
Aggregate stats across all 1792 tickers our top-EPS-revision screen has flagged over the past 76 days.
- Median return since detection
- +3.6%
- % of tickers in the green
- 57%
- Median return on winners
- +18.8%
- Large revisions captured
- 822
Past detection performance reflects the price change between when a ticker first entered our screen and the most recent observation. Not a forward-looking forecast.
Frequently Asked Questions
What is Faeth Therapeutics Inc's next-year EPS growth estimate?▾
As of 2026-06-15, Faeth Therapeutics Inc (SNSE) has a next-year EPS growth estimate of 91.78%, based on analyst consensus.
When was the latest EPS estimate revision for SNSE?▾
The most recent revision occurred on 2026-06-11, when analysts adjusted the next-year EPS growth estimate from 92.04% to 91.78%.
What sector and industry does Faeth Therapeutics Inc belong to?▾
Faeth Therapeutics Inc operates in the Healthcare sector, specifically the Biotechnology industry.
How often is this EPS estimate data updated?▾
EPS revision data is refreshed daily from analyst consensus estimates. SNSE appears on this page because it was flagged by our daily top-EPS-revision-performer screen.
EPS revision data sourced from analyst consensus estimates, refreshed daily. Faeth Therapeutics Inc (SNSE) appears here because it was detected by our daily top-EPS-revision-performer screen.
← All reports